Pharmaceutical company POZEN has entered into a Settlement Agreement with Teva Pharmaceuticals USA over a US patent infringement suit related to Teva’s filing of an Abbreviated New Drug Application to market a generic version of the migraine drug Treximet(R).

Treximet(R) (sumatriptan/naproxen sodium) is marketed by POZEN’s exclusive US licensee, GlaxoSmithKline.

Under the terms of the agreement, Teva will be dismissed without prejudice from the consolidated litigation but will still be bound by the outcome of as yet unresolved litigation against Par Pharmaceutical, Alphapharm, and Dr Reddy’s Laboratories.

The parties have also agreed to file a stipulation of dismissal and order with the US District Court for the Eastern District of Texas.

The case is currently scheduled for trial in the fourth quarter of 2010.